Company and Industry Summary Company Overview - The company operates in the pharmaceutical industry, focusing on various segments including prescription drugs and health consumer products. The overall market is experiencing pressure, with a decline in hospital markets and a shift towards online sales growth [1][2]. Key Financial Performance - In 2024, the company reported a revenue of 4.435 billion yuan, a decrease of 2.59% year-on-year. However, net profit increased by 9.67% to 788 million yuan [2]. - The weighted average return on equity was 19.58%, up by 1.9 percentage points year-on-year, indicating improved profitability [2]. - Research and development (R&D) investment intensity reached 10.82%, an increase of 0.53 percentage points year-on-year, reflecting a commitment to innovation [2]. Industry Dynamics - The pharmaceutical industry is facing overall pressure with localized breakdowns. The consumer market is growing cautiously, while the hospital market is expected to decline [1]. - The online market is maintaining rapid growth, presenting both opportunities and challenges for the company [1]. Product Performance - The pharmaceutical industrial revenue decreased by 2.79%, but the gross margin remained stable. Key products in the gastrointestinal and respiratory categories contributed over 60% of total revenue [2]. - The company’s health consumer products segment is undergoing restructuring, with a focus on high-end and functional products. However, this segment has seen a decline in revenue due to increased competition [6]. Cost Management - Sales expenses decreased by approximately 8.89% to 1.495 billion yuan, with a sales expense ratio of 33.7% [3]. - Management expenses remained stable at 229 million yuan, with a management expense ratio of 5.16% [3]. Strategic Initiatives - The company is enhancing R&D capabilities, with a 9.31% increase in R&D investment and a focus on building strategic partnerships with research institutions [8]. - A digital transformation strategy is being implemented to improve operational efficiency and enhance marketing capabilities [10]. - The company is committed to sustainable practices, aiming for carbon neutrality and increasing the use of green energy [9]. Future Outlook - For 2025, the company aims to achieve double-digit growth in both revenue and profit, focusing on strengthening core competitiveness and optimizing business operations [11]. - The company plans to accelerate investment and acquisition opportunities to enhance external growth capabilities [11]. Additional Insights - The company maintains a robust dividend policy, with a cumulative cash dividend payout exceeding 60% since its listing [3]. - The health consumer products segment is adopting a strategic model to enhance brand positioning and operational capabilities [6]. This summary encapsulates the key points from the conference call, highlighting the company's financial performance, industry challenges, strategic initiatives, and future outlook.

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]

March 30, 2025 04:09 PM GMT Jiangzhong Pharmaceutical Co. Ltd. | Asia Pacific 2024 Results NDR Takeaways Key Takeaways Although earnings have been volatile since Covid-19 ended, return metrics are still among the best for TCMs: 2024 revenue fell 2.6% and earnings rose 9.7% vs. 2023 (pre-announced in February note). Sales of its over-the-counter, prescription, and consumer health segments were +7.1%, -3.5%, and -47.3% vs. 2023. Thus, gains in the OTC segment continued to be offset by losses in the other two. ...

Investment Rating - The report maintains a "Buy" rating for the company [4][15]. Core Views - The company reported a total revenue of 4.435 billion yuan for 2024, a year-on-year decline of 2.59%, while the net profit attributable to shareholders was 788 million yuan, reflecting a year-on-year growth of 9.67% [2][8]. - The OTC segment is expected to see steady growth, supported by four major product categories, while the impact of prescription drug procurement is anticipated to diminish [12][11]. - The company is focusing on optimizing its health product structure and expanding through both organic growth and acquisitions [12][11]. Financial Performance Summary - For 2024, the company achieved total revenue of 44.35 billion yuan, a slight decrease of 2.59% year-on-year; net profit attributable to shareholders was 7.88 billion yuan, up 9.67% year-on-year; and the net profit excluding non-recurring items was 7.49 billion yuan, an increase of 6.43% year-on-year [2][8]. - The fourth quarter saw revenue of 13.06 billion yuan, a year-on-year decline of 0.80%, with net profit of 1.41 billion yuan, up 11.31% year-on-year [8]. - The company’s gross margin for 2024 was 63.52%, a decrease of 0.51 percentage points, primarily due to a significant drop in the gross margin of the prescription drug segment [14]. Business Segment Analysis - OTC Business: Revenue reached 32.66 billion yuan, a year-on-year increase of 7.07%, with a gross margin of 72.74% [9]. - Health Products: Revenue was 3.45 billion yuan, down 47.30% year-on-year, impacted by intensified competition and restructuring efforts [10]. - Prescription Drugs: Revenue totaled 7.93 billion yuan, a decline of 3.50% year-on-year, with a gross margin of 39.30% [10]. Future Outlook - For 2025, the company is expected to focus on a "big product, strong category" strategy, enhancing core competitiveness and anticipating revenue growth in the OTC segment driven by key products [11][12]. - The company aims to improve operational efficiency and profitability through continuous optimization of its business model and channel strategies [11].

Core Insights - Jiangzhong Pharmaceutical achieved a revenue of 4.435 billion yuan in 2024, a year-on-year decrease of 2.59%, while the net profit attributable to shareholders was 788 million yuan, an increase of 9.67% [1] - The OTC segment showed strong demand with a revenue of 3.266 billion yuan, reflecting a year-on-year growth of 7.07% [1] OTC Segment Performance - Key products in the gastrointestinal field, such as the core product "Gastrointestinal Digestive Tablets," saw a double-digit revenue growth, with sales reaching 169 million boxes, up by 10.91% year-on-year [1] - In the throat and cough segment, core products like "Compound Fresh Bamboo Liquid" and "Compound Grass Coral Tablets" contributed to double-digit growth, with sales of "Compound Grass Coral Tablets" reaching 37 million boxes, up by 4.05% year-on-year [1] - The nutritional supplement segment saw a revenue of over 200 million yuan, with sales of "Multivitamin Tablets" at 12 million boxes, down by 10.30% year-on-year [1] Health Business and Prescription Drug Segment - The health segment reported a revenue of 345 million yuan, a significant year-on-year decline of 47.30%, attributed to intensified industry competition and restructuring efforts [2] - The prescription drug segment generated a revenue of 793 million yuan, down by 3.50% year-on-year, with the decline narrowing due to the consolidation of traditional Chinese medicine pieces [2] Profitability and Cost Management - The company's gross margin was 63.52%, a decrease of 0.51 percentage points year-on-year, with the OTC segment having the highest gross margin at 72.74% [3] - The sales expense ratio improved to 33.70%, down by 2.33 percentage points year-on-year, while the net profit margin increased to 17.77%, up by 1.99 percentage points year-on-year [3] Dividend Policy and Future Outlook - The company announced a cash dividend of 7 yuan per 10 shares, resulting in a cash dividend ratio of 55.86%, with an overall annual dividend ratio reaching 95.77% [3] - The company aims for double-digit growth in revenue and profit by 2025, supported by a dual-driven strategy of "internal growth + external expansion" [3][4]

江中药业(600750)：持续优化业务结构 看好增长潜 力释放 核心观点 3 月19 日晚，公司发布2024 年年度报告，实现营业收入44. 35 亿元，同比下滑2.59%；实现归母净 利润7.88 亿元，同比增长9. 67%；实现扣非归母净利润7.49 亿元，同比增长6.43%，全年业绩符合预 期。展望2025 年，公司OTC 板块四大品类矩阵稳步增长，同时推进大健康产品结构优化，随着处方药 集采影响边际减弱，叠加内生+外延相结合拓展，看好公司增长潜力释放。 事件 公司发布2024 年年度报告 3 月19 日晚，公司发布2024 年年度报告，实现营业总收入44.35 亿元，同比下滑2.59%（调整 后）；实现归母净利润7. 8 8 亿元，同比增长9.67%（调整后）；实现扣非归母净利润7.4 9 亿元，同比 增长6.43%（调整后）；业绩符合我们此前预期。根据2 0 24年度利润分配方案，公司拟每10 股派发7 元（含税），共计派发4.40 亿元；同时公司于24 年10 月完成2024 年半年度利润分派，分派金额共计 3.15 亿元；2024 年年度现金红利总额合计为7. 55亿元，占年度合并报表中归母净利 ...

2025 年 03 月 26 日 江中药业(600750.SH) 24 年业绩稳健，OTC 收入延续增长 事件：公司发布 2024 年年报。 2024 年，公司实现营业收入 44.35 亿元，同比下降 2.59%（公司于 2024 年 12 月取得与本公司受同一企业控制的江中饮片 51%的股权， 此处为追溯调整后的数据，下同）；归母净利润 7.88 亿元，同比增长 9.67%；扣非归母净利润 7.49 亿元，同比增长 6.43%。Q4 单季度，公 司实现营业收入 13.06 亿元；归母净利润 1.41 亿元；扣非归母净利 润 1.34 亿元。 非处方药稳健增长，处方药和健康消费品收入承压。 分业务线来看，2024 年公司非处方药业务稳健增长,处方药业务和健 康消费品业务收入同比下滑。 （1）非处方药：2024 年公司聚焦品牌建设，以大单品引领强品类发 展，非处方药实现营业收入 32.66 亿元，同比增长 7.07%，其中脾胃 品类方面，10 亿级核心大单品健胃消食片收入规模实现双位数增长， 乳酸菌素片和贝飞达两大拳头产品收入规模均突破 6 亿元；咽喉咳 喘品类在核心产品复方鲜竹沥液和复方草珊瑚含片的牵引下，实 ...

Summary of the Conference Call for Jiangzhong Pharmaceutical Company Overview - Jiangzhong Pharmaceutical is a leading Chinese OTC (over-the-counter) pharmaceutical company, known for its well-established brands such as "Jiangzhong" and "Chuyuan" [10][24]. Key Financial Performance - **2024 Revenue**: 4.44 billion RMB, a decrease of 2.6% year-on-year [1] - **Net Profit**: 790 million RMB, an increase of 9.7% year-on-year, aligning with previous forecasts [1] - **Q4 2024 Revenue**: 1.31 billion RMB, a decrease of 0.8% year-on-year [1] - **Q4 2024 Net Profit**: 140 million RMB, an increase of 11% year-on-year [1] - **Dividend**: Total cash dividend of 750 million RMB, resulting in a 96% payout ratio and a 5.4% dividend yield [1] Business Segment Performance - **OTC Business**: Revenue increased by 7% year-on-year, impacted by a high base in the first half of the year [2] - **Prescription Drugs**: Revenue decreased by 3.5% year-on-year, affected by centralized procurement policies [2] - **Health Products**: Revenue saw a significant decline of 47.3% year-on-year due to business restructuring [2] - **Gross Margin**: Overall gross margin decreased by 0.06 percentage points to 64.0% [2] - **OTC/Health Products Gross Margin**: Increased by 1 percentage point to 72.7% and 0.6 percentage points to 37.7%, respectively [2] - **Prescription Drugs Gross Margin**: Decreased by 17.5 percentage points to 39.3% [2] - **Expenses**: Sales expenses decreased by 8.9%, while management expenses increased by 3.6% [2] Future Outlook - The company will hold a live earnings release conference on March 21 in Nanchang [3]. Valuation and Investment Rating - **Target Price**: 31.00 RMB, maintaining a "Buy" rating based on the SOTP (Sum of the Parts) valuation method [4][11]. - **Current Stock Price**: 21.93 RMB as of March 19, 2025 [5][24]. - **Market Capitalization**: 13.8 billion RMB (approximately 1.91 billion USD) [5]. Risk Factors - Key risks include: - Underperformance in OTC product sales [11] - Slower-than-expected progress in mergers and acquisitions [11] - Growth and margin improvements in the health business post-restructuring may not meet expectations [11] - Price volatility of key raw materials, particularly Taizishen [11] Additional Insights - The company has a projected stock price increase of 41.4% and a forecasted dividend yield of 3.9%, leading to an expected total return of 45.2% [9]. - The stock is rated as "Buy" with a significant upside potential compared to the market return expectations [19]. This summary encapsulates the essential financial metrics, business performance, future outlook, and investment considerations for Jiangzhong Pharmaceutical as discussed in the conference call.

Investment Rating - The investment rating for Jiangzhong Pharmaceutical (600750.SH) is "Buy" (maintained) [1] Core Views - The company is expected to achieve steady revenue and profit growth in 2024, with a projected revenue of 4.435 billion yuan (down 2.59% year-on-year) and a net profit of 788 million yuan (up 9.67% year-on-year) [4] - The report highlights the company's strong brand advantage in the gastrointestinal and intestinal medication sectors, which is anticipated to drive long-term growth potential [4] - The earnings forecast for 2025-2027 includes net profits of 891 million yuan, 1.008 billion yuan, and 1.131 billion yuan respectively, with corresponding EPS of 1.42 yuan, 1.60 yuan, and 1.80 yuan [4] Financial Performance Summary - In 2024, the company achieved a gross margin of 63.52% (down 1.79 percentage points) and a net margin of 19.40% (up 1.94 percentage points) [4] - The sales expense ratio decreased to 33.70% (down 3.38 percentage points), while the management expense ratio increased to 5.16% (up 0.37 percentage points) [4] - The non-prescription drug segment generated revenue of 3.266 billion yuan (up 7.07%) with a gross margin of 72.74% (up 1.04 percentage points) [5] - The prescription drug segment reported revenue of 793 million yuan (down 3.50%) with a gross margin of 39.30% (down 17.54 percentage points) [5] Business Segment Insights - The company is focusing on enhancing its OTC brand advantages and has seen significant growth in its core products, particularly in the gastrointestinal category [6] - The health consumer products segment is undergoing a transformation with a focus on self-developed products, which is expected to contribute to future growth [6] - The prescription drug segment is targeting specific demographics and therapeutic areas, including elderly care, women's health, and gastrointestinal treatments [6]